- Home
- MBRX vs EDSA Comparison
MBRX vs EDSA Comparison
Compare MBRX & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- EDSA
- Stock Information
- Founded
- MBRX 2015
- EDSA 2015
- Country
- MBRX United States
- EDSA Canada
- Employees
- MBRX N/A
- EDSA N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- EDSA Health Care
- Exchange
- MBRX Nasdaq
- EDSA Nasdaq
- Market Cap
- MBRX 17.1M
- EDSA 15.4M
- IPO Year
- MBRX 2016
- EDSA N/A
- Fundamental
- Price
- MBRX $0.68
- EDSA $2.24
- Analyst Decision
- MBRX Strong Buy
- EDSA Strong Buy
- Analyst Count
- MBRX 3
- EDSA 2
- Target Price
- MBRX $5.33
- EDSA $13.00
- AVG Volume (30 Days)
- MBRX 2.6M
- EDSA 21.9K
- Earning Date
- MBRX 08-12-2025
- EDSA 08-08-2025
- Dividend Yield
- MBRX N/A
- EDSA N/A
- EPS Growth
- MBRX N/A
- EDSA N/A
- EPS
- MBRX N/A
- EDSA N/A
- Revenue
- MBRX N/A
- EDSA N/A
- Revenue This Year
- MBRX N/A
- EDSA N/A
- Revenue Next Year
- MBRX N/A
- EDSA N/A
- P/E Ratio
- MBRX N/A
- EDSA N/A
- Revenue Growth
- MBRX N/A
- EDSA N/A
- 52 Week Low
- MBRX $0.25
- EDSA $1.55
- 52 Week High
- MBRX $3.65
- EDSA $5.00
- Technical
- Relative Strength Index (RSI)
- MBRX 53.28
- EDSA 52.38
- Support Level
- MBRX $0.62
- EDSA $2.02
- Resistance Level
- MBRX $0.70
- EDSA $2.28
- Average True Range (ATR)
- MBRX 0.07
- EDSA 0.13
- MACD
- MBRX -0.00
- EDSA -0.01
- Stochastic Oscillator
- MBRX 61.43
- EDSA 59.72
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.